Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01356173 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01356173 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 10 participants.
The verdict
NCT01356173, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetic (PK) of GDC-0349 administered once daily (QD), orally (PO).
Interventions
- DRUG GDC-0349
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01356173
The ClinicalTrials.gov registry entry for NCT01356173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GDC-0349 is the first listed.
NCT01356173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01356173 about?
NCT01356173 is a clinical study titled "Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma". This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetic (PK) of GDC-0349 administered once daily (QD), orally (PO).
What is the current status of trial NCT01356173?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2011-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01356173?
The interventions under investigation include: GDC-0349 (DRUG).
Who is sponsoring clinical trial NCT01356173?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.